The Effect of Polyunsaturated Fatty Acid (PUFA) Supplementation on Clinical Manifestations and Inflammatory Parameters in Individuals with Sjögren's Syndrome: A Literature Review of Randomized Controlled Clinical Trials.

Abstract

Sjögren's syndrome is a chronic autoimmune disease that causes dry mouth and eyes and can lead to non-Hodgkin's lymphoma in 5-10% of cases after 10 years. Clinical trials have shown that the oral administration of polyunsaturated fatty acids (PUFAs) seems to have a beneficial effect on Sjögren's syndrome. This literature review provides an overview of the effects of PUFA supplementation on clinical manifestations and inflammatory parameters in Sjögren's syndrome. We conducted a literature review using the PubMed, Biomed Central, and Cochrane Library electronic databases and using search terms "Sjögren" AND "omega-3"; and "omega-6" AND "fatty acids" AND "oil". This literature review followed the PRISMA guidelines and included randomized clinical trials in humans with or without a control group using the oral administration of PUFA. From 26 articles found in the databases, a total of 6 articles were included. Of these six trials, five trials showed an effect on clinical manifestations and three trials on inflammatory parameters. Most of the studies did not show a significant effect on the parameters analyzed. One study showed a significant improvement in dry keratoconjunctivitis compared to the control group. The results suggest that PUFAs may improve inflammatory parameters in patients with Sjögren's syndrome. This literature review supports the idea that the oral administration of PUFA may possess a potential effect on clinical manifestations. However, due to the limited number of studies and the heterogeneity of clinical trial methodology, further investigations should be employed. Understanding the potential mechanism of action of PUFAs on clinical biomarkers in Sjögren's syndrome may clarify their importance in clinical practice for health professionals.